// App-Quantinova.ai

: Model of the Impact of Delayed Inhibitor Development on Cumulative Breakthrough Bleeds and Costs in Persons with Hemophilia A Receiving Emicizumab Prophylaxis

Researchers

Presenter

  • Robert F. Sidonio

Principal Investigators

  • Anisha Patel

  • Shelby Corman

  • Stephen Chaplin

  • Karina Raimundo

Medical Centers

  • Emory University, Aflac Cancer and Blood Disorders Center, Childrens Healthcare of Atlanta, Atlanta, GA

  • Genentech, Inc., South San Francisico, CA

  • Pharmerit International, Bethesda, MD

  • Pharmerit International, Oxford, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • Alpha-1-microglobulin/bikunin precursor

Drug/Treatment

  • rFVIIa

  • Prothrombin complex

  • Regain

  • FVIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved